Drugs by condition
Drugs approved for enlarged prostate (bph)
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
7
Still marketed, NDA or BLA
Drug classes
4
Novel drugs
5
New molecular entities and new biologics
In development
1
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for enlarged prostate (bph).
- Gemtesa (Vibegron) · Sumitomo Pharma Am NovelDec 23, 2020
- Jalyn (Dutasteride, Tamsulosin Hydrochloride) · Waylis Therap Jun 14, 2010
- Cardura Xl (Doxazosin Mesylate) · Viatris Feb 22, 2005
- Cialis (Tadalafil) · Lilly NovelOrphanNov 21, 2003
- Uroxatral (Alfuzosin Hydrochloride) · Advanz Pharma NovelJun 12, 2003
All approved drugs for enlarged prostate (bph), by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 73 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
5-alpha Reductase Inhibitor (2)
beta3-Adrenergic Agonist (1)
- Gemtesa Vibegron · Sumitomo Pharma Am · 2020
Phosphodiesterase 5 Inhibitor (1)
- Cialis Tadalafil · Lilly · 2003
Class not listed in FDA's data (3)
- Uroxatral Alfuzosin Hydrochloride · Advanz Pharma · 2003
- Cardura Doxazosin Mesylate · Viatris · 1990
- Cardura Xl Doxazosin Mesylate · Viatris · 2005
Drugs in development for enlarged prostate (bph)
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- N0728Phase 31 trial
Eurofarma Laboratorios S.A. · Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
1 discontinued brand-name drugs whose label still names it
- Tezruly Terazosin Hydrochloride
More on enlarged prostate (bph): recruiting trials · published research
Related in kidney and urology: Chronic kidney disease · IgA nephropathy · Overactive bladder · Erectile dysfunction
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.